Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. (NASDAQ: ACON) is a leading healthcare technology company specializing in the innovative use of Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. Their flagship product, Nociscan, is a unique Software as a Service (SaaS) platform that noninvasively assists physicians in distinguishing between painful and nonpainful discs in the spine. By leveraging advanced MRS technology, Nociscan helps to identify the specific source of chronic low back pain (cLBP), a condition affecting 266 million people globally.
Nociscan generates reports based on MRS data collected from MRI machines, quantifying chemical biomarkers associated with disc pain. This data enables physicians to tailor treatment strategies optimally. The company derives its revenue primarily from the delivery of these Nociscan reports to medical professionals across the United States, enhancing their ability to make informed clinical decisions.
Recent developments highlight the company’s accelerated growth and significant milestones. Aclarion recently completed its 1,000th commercial Nociscan exam, marking an exciting phase of adoption. Moreover, the company is expanding Nociscan's compatibility beyond Siemens MRI machines, increasing its accessibility worldwide. The strategic partnership with Alphatec Spine, Inc. aims to integrate Nociscan into ATEC's AlphaInformatiX platform, providing comprehensive data to improve surgical decision-making for spine surgery.
The company is also initiating the pivotal multicenter, prospective, randomized CLARITY trial to validate superior surgical outcomes when Nociscan is integrated into surgical decision processes. Furthermore, Aclarion’s involvement in the LIFEHAB Trial in Norway underscores its commitment to advancing scientific understanding of chronic low back pain and improving patient outcomes.
Aclarion’s innovative approach is well-supported by a robust patent portfolio, including 22 U.S. patents and numerous international patents. The company's mission is to set a new standard of care in spinal diagnostics by offering noninvasive, data-driven insights that enhance the effectiveness of low back pain treatments.
Aclarion, Inc. (Nasdaq: ACON) announced that its Nociscan AI solution played a key role in a study to better understand Modic changes (MC) in chronic low back pain (cLBP) patients. The study, presented at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024, utilized Nociscan to measure intradiscal propionic acid (PA) levels adjacent to vertebral endplates with MC.
The research, conducted by the REACH Center at UCSF, aimed to clarify the biopsychosocial mechanisms of cLBP. Results suggest that PA levels may be useful in understanding why some MC patients improve or respond to treatment while others do not. Nociscan's ability to noninvasively quantify chemical biomarkers associated with disc pain could potentially lead to personalized treatment plans for cLBP patients, including the possibility of using antibiotics as a first-line treatment for those with high PA levels.
Aclarion, Inc. (Nasdaq: ACON) has provided a corporate update on their Nociscan AI technology, which aids in identifying chronic low back pain sources. Key milestones include:
1. Three of four largest private UK insurers now cover Nociscan
2. Partnership with ten prominent KOL surgeons in the US
3. Strategic partnership with ATEC to expand KOL network
4. Multiple commercial agreements in key US markets
5. Participation in NIH's BEST Trial with 800+ patients
6. Launch of CLARITY, a flagship clinical study
The company's technology is protected by 23 US patents and 17 international patents. Aclarion aims to establish Nociscan as a standard of care for chronic low back pain, addressing a $134 billion annual healthcare expenditure in the US.
Aclarion (NASDAQ: ACON) has announced the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. This randomized controlled trial is comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for 202 patients with chronic low back pain. Nociscan, Aclarion's technology, uses magnetic resonance spectroscopy (MRS) biomarkers to help identify patient improvement following treatment.
The trial began enrolling patients in Q2 2024, with six patients completing Nociscan exams by late August. Aclarion's CEO, Brent Ness, expressed excitement about the trial's progress and Nociscan's potential role in determining optimal treatment options. The company is also involved in other research studies, including trials in Rome and two NIH studies, as it aims to establish Nociscan as the gold standard for disc treatment decisions in low back pain research.
Aclarion, Inc. (Nasdaq: ACON) has launched a program to develop a statewide network of providers in New Jersey utilizing Nociscan for personal injury and workers compensation cases. Led by Dr. Justin Kubeck of Ocean Pain and Spine, the initiative aims to improve objective evaluation of chronic low back pain patients in these complex legal scenarios. Nociscan's AI technology measures biomarkers in lumbar discs correlated to pain and structural integrity, providing objective data for treatment recommendations and legal defenses.
The average settlement for personal injury claims involving neck and back in New Jersey is $918,967, while work-related accidents causing such injuries have a national average settlement of $148,750. Aclarion plans to expand this model to other U.S. markets, targeting a population well-suited for advanced biomarker identification through the Nociscan platform.
Aclarion, Inc. (Nasdaq: ACON) has expanded its Clinical Utility and Economic (CLUE) Trial to New Jersey, with Dr. Justin Kubeck of Ocean Pain and Spine joining the study. The CLUE trial aims to demonstrate how Nociscan's AI-generated data impacts treatment decisions for chronic low back pain. Nociscan is Aclarion's SaaS platform that noninvasively helps physicians identify painful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain.
Dr. Kubeck is the second surgeon to join CLUE, following Dr. John Keller in Michigan. Aclarion expects more spine surgeons to participate, rapidly providing data to payers on Nociscan's impact on treatment planning. The company aims to address the global issue of degenerative spine disease and low back pain, which affects 266 million people worldwide.
Aclarion (NASDAQ: ACON) has launched the Clinical Utility and Economic (CLUE) Trial to quantify how often Nociscan's AI-generated biomarker data changes surgical treatment plans for chronic low back pain. The multi-center study aims to provide insights into the real-world value of Nociscan as a decision support tool. Surgeons will determine their treatment plan before and after receiving Nociscan data, allowing Aclarion to assess the tool's influence on surgical decisions.
The CLUE trial complements the ongoing CLARITY study, which focuses on demonstrating improved surgical outcomes with Nociscan. CLUE's format is inspired by HeartFlow's evidence strategy, which led to changes in coronary artery disease assessment. Aclarion expects multiple physicians and sites to enroll in CLUE in the coming months, adding practical data to their expanding clinical evidence base.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis, has announced its participation in the upcoming Virtual Investor Summit on August 20th, 2024. The company, which utilizes biomarkers and proprietary augmented intelligence algorithms to assist physicians in locating chronic low back pain sources, will be presenting at 4:00 PM ET.
Investors interested in attending the presentation can access it via the provided webcast link. Additionally, there's an opportunity for one-on-one meetings with Aclarion's management team, which can be arranged through the Investor Summit Group's registration process.
Aclarion, Inc. (Nasdaq: ACON) has announced its first commercial agreement in Michigan with Sheridan Community Hospital. This agreement brings Nociscan, Aclarion's innovative solution for identifying chronic low back pain, to central Michigan and to Dr. John Keller, a leading neurosurgeon and Aclarion medical advisor.
Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It objectively quantifies chemical biomarkers associated with disc pain, providing critical insights when used with other diagnostic tools.
This agreement is part of Aclarion's strategy to expand access to Nociscan in the US market, following recent insurance coverage announcements in the UK. It represents a step towards potential payer coverage in the United States.
Aclarion (NASDAQ: ACON) has achieved a significant milestone by securing coverage for its Nociscan technology from Vitality, the third major private health insurer in the UK. This addition means Aclarion now has coverage from 3 of the 4 largest private health insurers in the UK, providing access to nearly 60% of patients with private health insurance in the Greater London market.
Nociscan, a SaaS platform that helps physicians identify the location of chronic low back pain, is gaining traction in the UK healthcare market. The London Clinic, a renowned independent hospital, has played a important role in demonstrating Nociscan's value and securing payer coverage. Aclarion's CEO, Brent Ness, expects this success to be replicated across their 10 KOL sites globally.
With private medical insurance becoming increasingly popular in the UK, these coverage decisions represent a significant shift in Aclarion's business model, providing a clear path to commercialization in the UK market.
Aclarion achieved a significant milestone with Aviva, a top UK private medical insurer, covering Nociscan, its AI-driven diagnostic tool for chronic low back pain. This coverage extends Nociscan's availability to 45% of patients with private insurance in Greater London, joining AXA, which already provides coverage. This development marks a important step in gaining broader market adoption and potential value creation for Aclarion. Nociscan, the first evidence-supported SaaS platform, helps physicians noninvasively identify painful lumbar discs by quantifying chemical biomarkers. The London Clinic is among the premier institutions adopting this technology.
FAQ
What is the current stock price of Aclarion (ACON)?
What is the market cap of Aclarion (ACON)?
What does Aclarion, Inc. do?
What is Nociscan?
How does Aclarion generate revenue?
What recent achievements has Aclarion made?
What is the CLARITY trial?
What partnerships has Aclarion formed?
What is the significance of Nociscan's compatibility with different MRI machines?
What is the LIFEHAB trial?
How does Nociscan improve surgical outcomes?
What is Aclarion's patent portfolio like?
